NeuroOne Medical regains compliance with Nasdaq listing requirements

NeuroOne Medical (NMTC) Technologies announced that it has regained compliance with the Nasdaq Capital Market’s continued listing standard for the minimum share price requirements under Nasdaq Listing Rule 5550(a)(2). The company received a letter on February 3, 2025 from the Listings Qualifications Hearing Department of Nasdaq that the company’s bid price deficiency had been cured and that the company was in compliance with all applicable listing standards. Based on the foregoing, the previously scheduled Nasdaq hearing has been cancelled and the matter is now closed. “We are pleased to announce that we have regained compliance with Nasdaq’s share price listing standards and are grateful to our shareholders for their patience during this time,” said Dave Rosa, CEO of NeuroOne. “We remain focused on driving sustainable shareholder value over the long term as we successfully penetrate the market with our disruptive OneRF Ablation System, the first and only FDA-cleared device for RF ablation in the brain.”